Tevimbra

targets

all catalysts(0)

nothing on the calendar yet

News(7)

• Solstice rises with $225M to develop next-gen CTLA-4 drug from China
  Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from…
  biospace · 24d ago
• Mid-cap biotechs join Trump’s latest round of drug pricing deals
  Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
  biopharma_dive · 1mo ago
• Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
  Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
  biospace · 1mo ago
• New Jazz cancer drug approval could drive blockbuster sales
  Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
  biopharma_dive · 1mo ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 2mo ago
• Akeso, Summit drug extends survival in closely watched lung cancer trial
  Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
  biopharma_dive · 4mo ago
• OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
  Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
  onclive · 4mo ago